In the field of nuclear medicine, it is necessary to perfect non-invasive diagnostic methods, and PulmoBioTech is contributing greatly to this need. The company recently announced the completion of bio-distribution studies concerning its PulmoBind molecular imaging agent.
The process of imaging on a cellular level requires the use of specialized molecules which are chemically engineered to bind to specific cells in the body, and these are then bonded to radioactive tracers. PulmoBind is a bonding agent that has been found to surpass those traditionally used in the field on several points. Essentially, it is a totally harmless substance known as adreno medullin which, upon injection, travels to and bonds with the tissue in the lungs more effectively than commonly used albumin macro-aggregates (AMAs). PulmoBind is safer as well, and provides the ability to capture images that are not possible with the older method.
Perhaps the best reason to consider PulmoBind a significant advancement in medicine is that, unlike AMAs, it will cause absolutely no damage to the patient’s lungs. The substance serves its purpose, and is subsequently flushed from the body via the kidneys and bladder in a matter of four hours. Not to mention that this is all possible without requiring hospitals to purchase expensive equipment upgrades; PulmoBind simply replaces the obsolete AMAs. The scientists at PulmoBioTech are not only offering progress to patients with pulmonary problems, but to the entire field of nuclear medicine.
Let us hear your thoughts: Pulmo BioTech, Inc. Message Board